StockData
Scribe Therapeutics, Inc. logo

Scribe Therapeutics, Inc. (SCTX) stock

SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$15.77+0.40 (+2.60%)

Close on Nov 17, 2026Market cap $39.19MP/E –Yield –

Scribe Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.40M–
Q2 FY2025Jun 30, 2025-$11.63M–

More Scribe Therapeutics figures

See a number that looks wrong?